ASH: American Society of Hematology Annual Meeting & Exposition

Researchers evaluated the safety, feasibility, and effectiveness of intranasal fentanyl in an adult population.

Social determinants of health (SDOH), such as financial disparities or lack of insurance, create barriers to accessing breakthrough therapies like BTK inhibitors among patients with CLL and SLL.

Three posters presented at the 65th American Society of Hematology Annual Meeting and Exposition looked into the efficacy and safety of the therapies.

Data from the Surveillance, Epidemiology, and End Results (SEER) database were reviewed.

Six posters presented at the 65th American Society of Hematology Annual Meeting and Exposition looked at how treatments are impacting care for this patient population.

Understanding the adverse event profile of bispecific antibodies can aid treatment selection and improve patient outcomes.

Results of the phase 3 PERSEUS study were presented at the 2023 ASH Annual Meeting and Exposition.